| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/17/2004 | CA2295861C Method of preparing a transgenic non-human animal expressing p25 |
| 08/17/2004 | CA2258153C Hepatocyte growth factor receptor agonists and uses thereof |
| 08/17/2004 | CA2212010C Extracts of shark cartilage, process of production and uses thereof |
| 08/12/2004 | WO2004067731A1 New strains of bifidobacterium having the ability to produce glutamine |
| 08/12/2004 | WO2004067724A2 Methods of identifying and designing cell surface receptor inhibitors |
| 08/12/2004 | WO2004067678A1 Antioxidative composition and composition for external use |
| 08/12/2004 | WO2004067554A2 Compositions and methods of tolerizing a primate to an antigen |
| 08/12/2004 | WO2004067037A1 Intestinal environment controlling agent for oral use and normal intestinal flora growing kit for oral use |
| 08/12/2004 | WO2004067036A1 Devices and compositions containing boron and silicon for use in neutron capture therapy |
| 08/12/2004 | WO2004067028A1 Compound for attenuating reaction of recipient tissues to an exogenic material and method for preparing an implant/transplant for contacting tissues of the organism of said recipient |
| 08/12/2004 | WO2004067022A2 Use of a mixture containing neuropeptides and steroids for treating disturbances of psychosocial experiences and behaviour |
| 08/12/2004 | WO2004067016A1 Use of a nano-copper powder in preparation of the medicaments in preventing and treating of osteoporosis and fracture |
| 08/12/2004 | WO2004067014A1 Solid preparation for dialysis and process for producing the same |
| 08/12/2004 | WO2004067013A1 Compositions and methods for restoring bacterial flora |
| 08/12/2004 | WO2004067006A1 Combination of a pde iv inhibitor and a tnf-alpha antagonist |
| 08/12/2004 | WO2004067003A1 Medicine for prevention of and treatment for arteriosclerosis and hypertension |
| 08/12/2004 | WO2004067002A2 SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT |
| 08/12/2004 | WO2004066990A2 Methods of treating lower urinary tract disorders using sodium channel modulators |
| 08/12/2004 | WO2004066987A2 Use of sodium channel modulators for treating gastrointestinal tract disorders |
| 08/12/2004 | WO2004066978A1 Powder pharmaceutical compositions |
| 08/12/2004 | WO2004066977A1 Solid agent for dialysis and process for producing the same |
| 08/12/2004 | WO2004066971A1 Composition for preventive treatment of cold sores |
| 08/12/2004 | WO2004066963A2 N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| 08/12/2004 | WO2004066956A2 Uses of integrin alphavbeta3 antagonists |
| 08/12/2004 | WO2004066943A2 Methods for diagnosis anf monitoring of neurological disease by detection of an encephalotoxin |
| 08/12/2004 | WO2004066940A2 Compositions and methods containing substituted quinolines and substituted diphenylsulfones |
| 08/12/2004 | WO2004066935A2 Sensitive proteasome sensor constructs and methods for their design and use |
| 08/12/2004 | WO2004066932A2 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 08/12/2004 | WO2004066931A2 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 08/12/2004 | WO2004066924A2 Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
| 08/12/2004 | WO2004066732A1 Desinfecting nitrous acid compositions and process for using the same |
| 08/12/2004 | WO2004057031A3 Methods for identifying therapeutic agents of atherosclerotic plaque lesions |
| 08/12/2004 | WO2004056762A3 Novel aminobenzophenone compounds |
| 08/12/2004 | WO2004056311A3 Stimuli-responsive systems for controlled drug delivery |
| 08/12/2004 | WO2004052286A3 Tyrosine kinase inhibitors |
| 08/12/2004 | WO2004050037A3 Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
| 08/12/2004 | WO2004046070A3 Modulation of proteins by phenolic compoudns |
| 08/12/2004 | WO2004045718A3 Treatment of cognitive dysfunctions' |
| 08/12/2004 | WO2004045593A3 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| 08/12/2004 | WO2004043392A3 Mucin synthesis inhibitors |
| 08/12/2004 | WO2004037262A3 Immediate release topical pharmaceutical formulation for enhancement of female sexual desire and responsiveness |
| 08/12/2004 | WO2004026311A3 Use of specific inhibitors of tyrosine kinases for immunomodulation |
| 08/12/2004 | WO2004024186A3 Treatment of cyclooxygenase-3 mediated diseases and disorders |
| 08/12/2004 | WO2004022032A3 Pharmaceutical dosage form comprising a sulfite compound |
| 08/12/2004 | WO2004021972A3 Pharmaceuticals formulations and methods for modified release of statin drugs |
| 08/12/2004 | WO2004015131A3 Hepatitis c virus assays |
| 08/12/2004 | WO2004007531A3 Activated checkpoint therapy and methods of use thereof |
| 08/12/2004 | WO2004002999A3 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 08/12/2004 | WO2003051182A3 Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia |
| 08/12/2004 | WO2003039484A3 Novel compositions and methods for cancer |
| 08/12/2004 | WO2003029293A3 Modulators of notch ic protease activity for use in immunotherapy |
| 08/12/2004 | WO2003026573A3 Screening and selection methods for statin drug combinations |
| 08/12/2004 | WO2003023028A9 Fungal glyoxal oxidases |
| 08/12/2004 | WO2002076395A3 Agents and methods for treatment of cancer |
| 08/12/2004 | US20040158288 Method and apparatus for treating tumors using low strength electric fields |
| 08/12/2004 | US20040158137 Integrated poration, harvesting and analysis device, and method therefor |
| 08/12/2004 | US20040158092 for example, N-(N-acetyl-L-cysteinyl)-S-acetylcysteamine; by protecting the N-acyl-L-cysteine to form an intermediate compound and then coupling intermediate compound with S-acylcysteamine hydrochloride or with thiazolidine |
| 08/12/2004 | US20040158037 Amino acid loaded trityl alcohol resins, method of production of amino acid loaded trityl alcohol resins and biologically active substances and therapeutics produced therewith |
| 08/12/2004 | US20040157934 Central nervous system disorders; psychological disorders ; administering dosage og dopamine, serotonin and sibutramine |
| 08/12/2004 | US20040157917 Central nervous system disorders; psychological disorders |
| 08/12/2004 | US20040157915 Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| 08/12/2004 | US20040157909 Modulating protein kinase signal transduction; anticancer agents |
| 08/12/2004 | US20040157908 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 08/12/2004 | US20040157895 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases |
| 08/12/2004 | US20040157893 Pyrazole compounds useful as protein kinase inhibitors |
| 08/12/2004 | US20040157875 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders |
| 08/12/2004 | US20040157870 for treating or preventing attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder |
| 08/12/2004 | US20040157869 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 08/12/2004 | US20040157867 Pyrimidine phosphorylase as a target for imaging and therapy |
| 08/12/2004 | US20040157862 estrogen agonist/antagonist is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol; A kit for use by a consumer to treat osteoarthritis, the kit comprising: estrogen agonist/antagonist; COX-2 inhibitor |
| 08/12/2004 | US20040157848 effective in treating the symptoms arising from outbreaks of HSV infections, as well as methods of eliminating the virus from the body |
| 08/12/2004 | US20040157840 Rifalazil compositions and therapeutic regimens |
| 08/12/2004 | US20040157837 Combinations for the treatment of fungal infections |
| 08/12/2004 | US20040157822 Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1 |
| 08/12/2004 | US20040157812 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| 08/12/2004 | US20040157809 androgen receptor blocker is flutamide and the insulin sensitizer is metformin; optionally with contraceptive |
| 08/12/2004 | US20040157786 Taxol, Taxotere and their analogues, which possess noteworthy antitumour and antileukaemic properties, are especially useful in the treatment of cancers of the ovary, breast or lung |
| 08/12/2004 | US20040157785 Combination therapy comprising anti-diabetic and anticonvulsant agents |
| 08/12/2004 | US20040157773 Farnesyl protein transferase inhibitors for treating cachexia |
| 08/12/2004 | US20040157767 Targeted delivery of bioaffecting compounds for the treatment of cancer |
| 08/12/2004 | US20040157766 Topical pharmaceutical and/or cosmetic dispense systems |
| 08/12/2004 | US20040157323 Biomaterial derived from vertebrate liver tissue |
| 08/12/2004 | US20040157292 Sperm-specific cation channel, CatSper1, and uses therefor |
| 08/12/2004 | US20040157282 Regulation of human dual specificity protein phosphatase 7-like protein |
| 08/12/2004 | US20040157261 Kv10.1, a novel voltage-gated potassium channel from human brain |
| 08/12/2004 | US20040157259 Novel human ion channel protein and polynucleotides encoding the same |
| 08/12/2004 | US20040157250 Contacting a test compound with an expression system comprising an ABCA1 polynucleotide and detecting a change; use in treating coronary artery disease |
| 08/12/2004 | US20040157229 Methods of profiling gene expression, protein or metabolite levels |
| 08/12/2004 | US20040157222 for drug screening anti-cancer, asthma, obesity, diabetes, central nervous system and cardiovascular disorder drugs; genetic engineering; kits |
| 08/12/2004 | US20040156931 Administration of capsaicinoids |
| 08/12/2004 | US20040156922 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators |
| 08/12/2004 | US20040156914 Slow release protein polymers |
| 08/12/2004 | US20040156913 poly(alpha-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, or a polycyanoacrylate, formed using detergents; biologically active macromolecule adsorbed on surface |
| 08/12/2004 | US20040156903 Metering and packaging of controlled release medication |
| 08/12/2004 | US20040156900 core of an active agent and a swelling agent, and a coating of film forming polymer, which swells when it imbibes fluid from the core and ruptures to release the drug in a pulse in a reliable manner |
| 08/12/2004 | US20040156882 high energy neutraceutical composition that improves absorption of nutrients, increaseds appetite, promotes weight gain, or reduces calorie deficit; less than 3% by weight fat; suitable for administration through a tube |
| 08/12/2004 | US20040156848 Therapeutic uses of factors which inhibit or neutralize MIF activity |
| 08/12/2004 | US20040156840 A preferred IgM is autoantigen IgM, in particular anti-ds-DNA and anti-phospholipid IgM; may be mixed with an antiinflammatory agent, an immunosuppressive agent and/or a cytostatic agent |
| 08/12/2004 | US20040156791 Heating antipsychotic drug to vaporize; cooling to form condensation aerosol; kit for dispensing thin coating |
| 08/12/2004 | US20040156790 Delivery of drug esters through an inhalation route |